Does the world's bestselling asthma drug sometimes kill the patients it is supposed to help? Frank A. Dittig was recovering from a nasty bout of pneumonia in the spring of 2004 when he developed a ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) received a boost on Monday from a decision by Express Scripts (ESRX.O), the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent ...
GlaxoSmithKline’s Andrew Witty has spent his entire CEO stint fending off concerns about the arrival of generic Advair. But on his final quarterly conference call as helmsman, he finally laid out just ...
GSK can breathe easy as new CEO Emma Walmsley takes over, following the FDA rejection of Mylan’s generic version of big-selling respiratory drug Advair. The US patent on Advair (fluticasone+salmeterol ...
GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business. The FDA approved the ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...
GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results